Portfolio

Extract from the portfolio of companies presently invested in:

VLST Corporation www.vlstcorp.com VLST Corporation is a privately held biotechnology company dedicated to the streamlined discovery and development of novel therapeutics for the treatment of inflammatory and autoimmune disorders. The Company’s proprietary technology platform allows for the efficient identification of high quality, validated drug targets based on a thorough understanding of virulence gene products and their function. Such an approach offers the opportunity to improve the prioritization of drug targets and reduce costs by improving the clinical success rate. The VLST discovery platform has primary applications for the treatment of rheumatoid arthritis, Crohn’s disease, multiple sclerosis, lupus and diabetes. Formed in 2004, VLST includes preeminent scientific co-founders and a seasoned leadership team. VLST was co-founded by Drs. Craig Smith and Steven Wiley. Dr. Smith and Dr. Ray Goodwin, a member of the VLST scientific advisory board, are co-inventors of Enbrel®, a biologic therapy for the treatment of several inflammatory disorders.
Osprey Pharmaceuticals USA www.ospreypharma.com Osprey Pharmaceuticals is a privately held biotechnology company based in San Francisco, CA, USA, focusing on the development and commercialization of Leukocyte Population Modulators (LPMs), a first-in-class family of therapeutic proteins. Osprey's broad technology platform is based on the critical insight that many chronic diseases are propagated by overabundant and overactive leukocytes. The company's proprietary LPMs selectively and systematically deplete disease-related leukocytes, e.g. macrophages, by selectively targeting the chemokine systems that regulate the activity of pathogenic leukocytes. Osprey’s most advanced LPM is currently in late preclinical development and has broad potential application within inflammatory diseases.
Pieris AG www.pieris-ag.com Pieris is a preclinical-stage company engaged in the discovery and development of Anticalins®, a novel class of targeted human protein therapeutics. Anticalins® are derived from Lipocalins; a diverse class of small evolutionary conserved proteins that are structurally similar to immunoglobulins. Based on human lipocalins, Pieris has created a panel of highly diverse Anticalin® libraries that allow for identification of novel binding proteins to multiple target categories such as large proteins, peptides or haptens. The Company is currently developing Anticalins® for therapeutic use in oncology and inflammatory diseases. Pieris is based in Freising, Germany.
Affimed Therapeutics AG www.affimed.com Affimed is a preclinical-stage company based in Heidelberg, Germany, specialising in the development of novel antibody formats on the basis proprietary human antibody libraries. Specifically, Affimed’s proprietary TandAb^TM and Fleximer^TM formats provide tetravalency and bispecificity which distinguishes them other similar formats. Furthermore, Affimed is the only company that makes and screens three different types of antibody gene libraries. Using its complementary technology platforms, the company has been able to establish a pipeline of promising novel product candidates for indications in oncology and autoimmune diseases.
Xencor, Inc. www.xencor.com Xencor, Inc., engineers optimized biotherapeutics using its proprietary Protein Design Automation® technology platform. The company is internally advancing both XPro^TM protein and XmAb^TM antibody drug candidates, and has recently initiated phase I clinical trials in Hodgkin and T cell lymphoma with their lead XmAb^TM program. In addition, Xencor is applying its suite of XmAb^TM antibody Fc domains to improve antibody drug candidates together with multiple partners, such as industry leaders Genentech, Roche, Centocor and MedImmune. Xencor is based in Monrovia, CA, USA.
TransTechPharma Inc. www.ttpharma.com TransTech Pharma is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule and protein therapeutics to fill unmet medical needs. TransTech Pharma's integrated Translational Technology^TM discovery platform allows for rapid and cost-efficient development of drug candidates within a range of in-house and collaborative projects. So far, TransTech Pharma’s discovery engine has delivered more than 15 clinical programs in multiple indications that are being developed internally or in collaboration with partners Pfizer and Merck. TransTech Pharma is based in High Point, NC, USA.
Transition Therapeutics Inc. www.transitiontherapeutics.com Transition Therapeutics Inc. is a publicly traded biopharmaceutical company (NASDAQ:TTHI, TSX:TTH) exploring novel therapeutics in multiple disease indications using its proprietary technologies. Through partnerships with Elan and Eli Lilly, Transition is developing therapeutic innovations that inhibit progression of Alzheimer's disease and Diabetes. Transition Therapeutics is based in Toronto, Canada.
Innate Pharma S.A.S. www.innate-pharma.com Innate Pharma S.A. is a publicly traded biopharmaceutical company (Paris:IPH.PA) specialised in developing first-in-class drugs targeting the innate immune system. Based on its proprietary discovery engine, which comprises three product platforms that target three different innate immune receptors, the Company has generated a pipeline of novel product candidates, three of which are in clinical development. Alongside the equity investment, Innate Pharma and Novo Nordisk A/S have a collaboration aiming at generating novel therapeutic antibodies to treat inflammatory diseases. Innate Pharma is based in Marseilles, France.